Advertisement

Topics

Asuragen Expands QuantideX® qPCR BCR-ABL Portfolio for Monitoring Molecular Response in ...

05:06 EDT 2 Aug 2017 | BioMedReports - Blog
Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and CFO
lhohlfeld@asuragen.com

Read more...

Original Article: Asuragen Expands QuantideX® qPCR BCR-ABL Portfolio for Monitoring Molecular Response in ...

NEXT ARTICLE

More From BioPortfolio on "Asuragen Expands QuantideX® qPCR BCR-ABL Portfolio for Monitoring Molecular Response in ..."

Quick Search
Advertisement